Comparative Pharmacology
Head-to-head clinical analysis: MYDRIACYL versus MYDRIAFAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYDRIACYL versus MYDRIAFAIR.
MYDRIACYL vs MYDRIAFAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anticholinergic agent that blocks muscarinic receptors in the eye, causing mydriasis and cycloplegia.
Antimuscarinic; blocks acetylcholine at muscarinic receptors in iris sphincter and ciliary muscle, causing mydriasis and cycloplegia.
For refraction: 1-2 drops of 0.5% or 1% solution topically in the eye(s), repeated every 5-10 minutes for up to 3 doses; for cycloplegia: 1-2 drops of 1% solution topically, repeated once after 5 minutes.
Administered as one drop of phenylephrine 2.5% and tropicamide 1% ophthalmic solution in each eye 15-20 minutes prior to examination; may repeat once in 5-10 minutes if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in adults; prolonged in elderly and patients with hepatic impairment
Terminal elimination half-life is 1.5 hours; prolonged to 3-4 hours in renal impairment.
Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 30%)
Renal: 80% as unchanged drug and metabolites; fecal: 20% via biliary excretion.
Category C
Category C
Mydriatic
Mydriatic